<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451619</url>
  </required_header>
  <id_info>
    <org_study_id>0524-155</org_study_id>
    <nct_id>NCT01451619</nct_id>
  </id_info>
  <brief_title>A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study to Assess the Pharmacodynamics of MK-0524 in Subjects With Moderate to Severe Erythematotelangiectatic Rosacea. (Protocol No. 155)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of
      rosacea and to determine the safety and tolerability profile of MK-0524 in participants with
      rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinician's Erythema Assessment (CEA) Scale Score from Baseline</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Self Assessment (PSA) Score from Baseline</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Laropiprant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laropiprant</intervention_name>
    <description>One 100-mg tablet orally once daily for 4 weeks</description>
    <arm_group_label>Laropiprant</arm_group_label>
    <other_name>MK-0524</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Laropiprant</intervention_name>
    <description>One tablet orally once daily for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe erythematotelangiectatic rosacea with moderate to severe erythema
             of facial lesion

          -  Generally healthy excluding rosacea

          -  Presence of telangiectasia

          -  Five or less facial inflammatory lesions

          -  Able to restrict diet in order to avoid foods/drinks (including alcohol) that are
             known to exacerbate the signs/symptoms of rosacea

          -  Females of childbearing potential must have negative serum pregnancy test and agree to
             use one form of contraception

        Exclusion Criteria:

          -  Diagnosis of skin disorders, including psoriasis, acne vulgaris, perioral dermatitis
             or atopic dermatitis that would interfere with the clinical evaluations of rosacea

          -  Using and unable to discontinue use of phosphodiesterase (PDE) 4 inhibitors,
             theophylline, niacin greater than 500 mg/day

          -  Known or suspected excessive alcohol intake

          -  Sensitivity to tetracyclines

          -  Ocular rosacea and/or blepharitis/meibomianitis

          -  Pregnant or breastfeeding

          -  Perimenopausal and has symptoms that cause flushing that may affect rosacea

          -  Initiated hormonal method of birth contraception within 4 months of baseline,
             discontinues use during the course of the study, or changes hormonal method within 4
             months

          -  Active mycobacterial infection of any species within 3 years

          -  History of mycobacterium tuberculosis infection

          -  History of recurrent bacterial infection

          -  Congenital or acquired immunodeficiency common variable immunodeficiency (CVID),
             Hepatitis B surface antigen positive or Hepatitis B core antibody positive

          -  Human immunodeficiency virus (HIV) infection

          -  Positive for hepatitis C antibodies

          -  Malignancy or has had a history of malignancy greater than 3 years prior

          -  Will continue to use any of the following treatments during the study: Systemic
             retinoids, therapeutic vitamin A supplements of greater than 10,000 units/day,
             systemic steroids, systemic antibiotics known to have an impact on the severity of
             facial rosacea, systemic treatment for acne, topical steroids, topical retinoids,
             topical acne treatments including prescription and over-the-counter (OTC)
             preparations, topical anti-inflammatory agents, topical antibiotics, topical imidazole
             antimycotics, cryodestruction or chemodestruction, dermabrasion, photodynamic therapy,
             acne surgery, intralesional steroids, X-ray therapy, pulse-dye laser, intense pulse
             light, astringents, abrasives, benzoyl peroxide products, sulfur containing washes,
             eye washes, Beta blockers, vasodilators, vasoconstrictors and/or chronic use (&gt;14
             days) of topical or systemic anti-inflammatory agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Krishna R, Guo Y, Schulz V, Cord-Cruz E, Smith S, Hair S, Nahm WK, Draelos ZD. Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: laropiprant in comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosacea. J Clin Pharmacol. 2015 Feb;55(2):137-43. doi: 10.1002/jcph.383. Epub 2014 Sep 4.</citation>
    <PMID>25142778</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

